Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-055 in Mucopolysaccharidosis Type II (Hunter Syndrome)
NCT05208281Phase 3Active, not recruiting
- Sponsor
- Generium
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of verenafusp alfa in mucopolysaccharidosis type II, sponsored by Generium. Started Nov 2021; status: active, not recruiting.
02
Drugs
verenafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT05208281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208281.